E3: Novel FBXO3 anti-inflammatories initially for bronchitis

Bill Chen, PhD Associate Professor, Division of Pulmonary, Allergy, and Critical Care Medicine

Rama Mallampalli, MD Professor and Vice Chair for Research
Director, ALI Center of Excellence
Division of Pulmonary, Allergy, and Critical Care Medicine

There are currently 14.2 million chronic bronchitis patients in the US; it is the 3rd leading cause of death. Existing therapy consists of antibiotics and corticosteroids that can have severe side affects, such as diabetes, stroke, and heart attack. The economic burden for treating chronic bronchitis and for the complications of existing therapy costs $5,300 per patient. E3 Therapeutics, Inc. has answered this need by developing a new class of novel anti-inflammatory compounds that target the FBXO3 protein, which plays a critical role in the inflammation leading to bronchitis. These compounds exhibit a long half-life, excellent bioavailability, limited adverse effects, and limited in vitro toxicity. This is a platform technology with the goal to develop and commercialize these compounds through E3 Therapeutics, entering the market initially with the bronchitis indication while continuing to develop compounds to target other diseases such as rheumatoid arthritis, COPD, and psoriasis.